Lord Abbett & CO. LLC boosted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 6.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 730,339 shares of the company's stock after buying an additional 46,119 shares during the period. Lord Abbett & CO. LLC owned 0.35% of Cellebrite DI worth $16,089,000 at the end of the most recent quarter.
Other large investors also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Cellebrite DI by 21.3% during the third quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock worth $7,202,000 after purchasing an additional 75,092 shares in the last quarter. Harbor Capital Advisors Inc. raised its position in shares of Cellebrite DI by 65.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 157,671 shares of the company's stock valued at $3,473,000 after buying an additional 62,320 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Cellebrite DI in the fourth quarter worth about $9,995,000. State Street Corp grew its stake in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock valued at $7,472,000 after acquiring an additional 30,052 shares in the last quarter. Finally, Teacher Retirement System of Texas purchased a new stake in Cellebrite DI during the 4th quarter valued at about $442,000. 45.88% of the stock is currently owned by hedge funds and other institutional investors.
Cellebrite DI Trading Up 0.4 %
CLBT opened at $19.64 on Friday. The stock's 50-day moving average price is $18.73 and its 200 day moving average price is $20.13. Cellebrite DI Ltd. has a 12-month low of $10.25 and a 12-month high of $26.30. The firm has a market cap of $4.70 billion, a price-to-earnings ratio of -14.13, a PEG ratio of 4.27 and a beta of 1.44.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. On average, research analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on CLBT. Needham & Company LLC restated a "buy" rating and set a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. JPMorgan Chase & Co. upped their target price on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Finally, Lake Street Capital raised their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $23.43.
Check Out Our Latest Stock Analysis on Cellebrite DI
About Cellebrite DI
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Articles
Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
